Completed PHASE4 INTERVENTIONAL 2-arm NCT00160680

ATAREAL (Antihistamine Treatment for Allergic Rhinitis in Real Life)

A Pilot, Open, Monocenter, Randomized Two Parallel Groups, Clinical Efficacy Trial: Comparison Continuous Versus on Demand Regimen of Treatment With Levocetirizine 5 mg Oral Tablets, Once a Day, in Adults Suffering From Persistent Allergic Rhinitis (PER) Over 6 Months

Sponsor: UCB S.A. - Pharma Sector

Conditions Rhinitis, Allergic, Perennial

Interventions Levocetirizine

Updated 8 times since 2017 Last updated: Aug 29, 2023 Started: Mar 1, 2005 Primary completion: Jun 1, 2006 Completion: Jun 1, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Rhinitis, Allergic, Perennial and is currently completed. UCB S.A. - Pharma Sector leads this study, which shows 8 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Sep 2023 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Sep 2023 [monthly]

Completed PHASE4
Feb 2019 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jun 2018 — Feb 2019 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UCB S.A. - Pharma Sector

Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Genova, Italy